Immunome (IMNM) Investor presentation summary

Strategic vision and leadership

• Aims to establish a premier targeted oncology company with a focus on delivering breakthroughs in oncology and expanding a differentiated pipeline leveraging proprietary technology.

• Leadership team has deep expertise and a track record of success in oncology drug development, commercialization, and capital raising.

• Runway expected to extend into 2028, supporting ongoing and future clinical development.

Varegacestat clinical and commercial highlights

• Varegacestat, an oral gamma secretase inhibitor, demonstrated exceptional Phase 3 results in desmoid tumors, meeting all primary and key secondary endpoints.

• Achieved 84% reduction in risk of progression or death vs placebo (HR 0.16, p<0.0001), 56% objective response rate, and 83% median tumor volume reduction.

• Statistically and clinically significant reduction in worst pain intensity at week 12, with benefits seen as early as week 4.

• Generally well-tolerated safety profile; most adverse events were grade 1 or 2, with no deaths reported.

• NDA submitted in April 2026; launch strategy targets standard of care status and broad patient access.

Pipeline and technology innovation

• Broad portfolio includes multiple ADCs (IM-1021, IM-1617, IM-1340, IM-1335) and a FAP-targeted radioligand therapy (IM-3050), with several INDs planned for 2026.

• Proprietary HC74 TOP1i payload designed to overcome resistance and improve therapeutic index, showing superior bystander effect and activity in resistant models.

• IM-1021 (ROR1 ADC) demonstrated objective responses in B-cell lymphoma patients and robust preclinical activity in solid tumors.

• IM-3050 (FAP radioligand) showed single-dose antitumor activity and tolerability, with first clinical site activated in March 2026.